Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.56 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.56 |
| ▸ | ITGAL | P20701 | 1/20 | 0.56 |
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.55 |
| ▸ | TACR1 | P25103 | 3/20 | 0.51 |
| ▸ | GHSR | Q92847 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30668967 | 0.97 | DPP3 (0.55) | ITGB2ICAM1ITGALDPP3TACR1 | |
| SCHEMBL29534382 | 0.95 | DPP3 (0.53) | ITGB2ICAM1ITGALDPP3TACR1 | |
| SCHEMBL29534025 | 0.95 | DPP3 (0.53) | ITGB2ICAM1ITGALDPP3TACR1 | |
| SCHEMBL29533342 | 0.95 | DPP3 (0.53) | ITGB2ICAM1ITGALDPP3TACR1 | |
| SCHEMBL6880238 | 0.91 | DPP3 (0.53) | ITGB2ICAM1ITGALDPP3TACR1 | |
| SCHEMBL6877616 | 0.91 | DPP3 (0.53) | ITGB2ICAM1ITGALDPP3TACR1 | |
| SCHEMBL14903300 | 0.89 | DPP3 (0.53) | ITGB2ICAM1ITGALDPP3TACR1 | |
| SCHEMBL29812309 | 0.89 | DPP3 (0.64) | ITGB2ICAM1ITGALDPP3TACR1 | |
| SCHEMBL22459075 | 0.87 | GHSR (0.55) | DPP3TACR1GHSRMEN1KMT2A | |
| SCHEMBL30921658 | 0.86 | ITGB2 (0.65) | ITGB2ICAM1ITGALDPP3TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113754719-B | Tripeptide and application thereof in preparation of medicines and health products for improving memory | 荣成泰祥食品股份有限公司 | 2023-08-04 | — | — | CN | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| CN-113754719-B | Tripeptide and application thereof in preparation of medicines and health products for improving memory | 荣成泰祥食品股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-113754719-B | Tripeptide and application thereof in preparation of medicines and health products for improving memory | 荣成泰祥食品股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ITGB2 3494/4885ICAM1 2949/4885ITGAL 2468/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ITGB2 3719/4885ICAM1 2371/4885ITGAL 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.